Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: A novel circular RNA hsa_circRNA_103809/miR-377-3p/GOT1 pathway regulates cisplatin-resistance in non-small cell lung cancer (NSCLC)

Fig. 1

Continuous low-dose cisplatin pressure changed the expression patterns of hsa_circRNA_103809, miR-377-3p and GOT1 in NSCLC cells. The parental CS-NSCLC cells (A549, H1299 and Calu-3) were subjected to continuous low-dose cisplatin treatment to generate CR-NSCLC cells (A549/DDP, H1299/DDP and Calu-3/DDP). a-c Cell proliferation abilities in CS-NSCLC and CR-NSCLC cells were determined by using the CCK-8 assay (Note: “Control: without cisplatin stimulation”). d-f Trypan blue staining assay was conducted to evaluate NSCLC cell viability. g Cell apoptosis ratio was measured by using the Annexin V-FITC/PI double staining method. Real-Time qPCR was used to examine the expression levels of (h) hsa_circRNA_103809, i miR-377-3p and j GOT1 mRNA in NSCLC cells. k Western Blot analysis was employed to determine the protein levels of GOT1 in NSCLC cells, full-length blots/gels are presented in Supplementary Figure S4. Each experiment was repeated at least 3 times. *P < 0.05

Back to article page